Cargando…
Oncometabolites and the response to radiotherapy
Radiotherapy (RT) is applied in 45–60% of all cancer patients either alone or in multimodal therapy concepts comprising surgery, RT and chemotherapy. However, despite technical innovations approximately only 50% are cured, highlight a high medical need for innovation in RT practice. RT is a multidis...
Autores principales: | Xiang, Kexu, Jendrossek, Verena, Matschke, Johann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429799/ https://www.ncbi.nlm.nih.gov/pubmed/32799884 http://dx.doi.org/10.1186/s13014-020-01638-9 |
Ejemplares similares
-
Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
por: Xiang, Kexu, et al.
Publicado: (2022) -
Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
por: Hansel, Christine, et al.
Publicado: (2021) -
A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance
por: Götting, Isabell, et al.
Publicado: (2020) -
Metabolic Rewiring and the Characterization of Oncometabolites
por: Beyoğlu, Diren, et al.
Publicado: (2021) -
Metabolism of cancer cells commonly responds to irradiation by a transient early mitochondrial shutdown
por: Krysztofiak, Adam, et al.
Publicado: (2021)